Elyse C Page (Elyse Page)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Gene Expression

Top Venues

Cancer gene therapy

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Laura N Eadie, Elias Lagonik, Elyse C Page, Caitlin E Schutz, Susan L Heatley, Barbara J McClure, Michelle O Forgione, David T O Yeung, Timothy P Hughes, Deborah L White
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood 144 (9) (2024)
Laura N Eadie, Elias Lagonik, Elyse C Page, Caitlin E Schutz, Susan L Heatley, Barbara J McClure, Michelle O Forgione, David T O Yeung, Timothy P Hughes, Deborah L White
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood 144 (9) (2024)
Laura N Eadie, Elias Lagonik, Elyse C Page, Caitlin E Schutz, Susan L Heatley, Barbara J McClure, Michelle Olivia Forgione, David T O Yeung, Timothy P Hughes, Deborah L White
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood (2024)
Paniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, Elyse C Page, Maxime François, Timothy P Hughes, David Yeung, Deborah L White
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia. Cancer gene therapy 29 (8-9) (2022)
Elyse C Page, Susan L Heatley, Laura N Eadie, Barbara J McClure, Charles E de Bock, Sofia A Omari, David T Yeung, Timothy P Hughes, Paul Q Thomas, Deborah L White
HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene (2021)
Charlotte E J Downes, Barbara J McClure, John B Bruning, Elyse C Page, James Breen, Jacqueline A Rehn, David T Yeung, Deborah L White
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia. NPJ precision oncology 5 (1) (2021)